HGF and SDF-1α Composition for Peripheral Artery Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for peripheral artery disease, such as ischemic limb disease, are inadequate, often resulting in severe pain and potential amputation or death, highlighting the need for a more effective therapeutic approach.
Innovation Solution
A pharmaceutical composition combining hepatocyte growth factor (HGF) or its isoforms with stromal cell-derived factor 1α (SDF-1α), or polynucleotides encoding these proteins, is developed to promote vascular endothelial cell migration and angiogenesis, offering a dual protein and gene therapy strategy for prevention and treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (drugs to expand blood vessels or surgical operations) are used for peripheral artery disease, then the treatment approach is simple and widely available, but the therapeutic effect is insufficient, leading to severe pain and potential amputation or death
Solution Approach 1:
The patent combines two different therapeutic agents (HGF and SDF-1α) into a single pharmaceutical composition to achieve synergistic therapeutic effects. This merging of multiple treatment mechanisms addresses the insufficient therapeutic effect of conventional single-modality treatments while maintaining practical applicability through a unified formulation.
Solution Approach 2:
The invention uses a composite pharmaceutical composition containing both HGF and SDF-1α proteins (or their encoding polynucleotides). This composite approach leverages the complementary mechanisms of action of the two components to enhance overall therapeutic efficacy beyond what either component could achieve alone.
2Reliability
If HGF and SDF-1α are used in combination for treating peripheral artery disease, then the therapeutic effect is significantly enhanced, but the complexity of the treatment increases
Solution Approach 1:
The patent merges HGF and SDF-1α into a single pharmaceutical composition that can be administered together, simplifying the treatment protocol despite the complexity of the dual-component formulation. This unified approach delivers both therapeutic agents simultaneously to achieve synergistic effects.
Solution Approach 2:
The pharmaceutical composition serves multiple therapeutic functions by incorporating both HGF (which promotes angiogenesis and cell migration) and SDF-1α (which recruits progenitor cells and enhances vascular formation). This multi-functionality addresses various aspects of peripheral artery disease pathophysiology within a single treatment modality.
Data Source
Figure 1
Figure 2a~2b
Figure 3
AI summary
The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1α (SDF-1α); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1α. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1α or a polynucleotide codes a protein thereof.